Wells Fargo raised the firm’s price target on Cencora (COR) to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is ...
Shares of Cencora Inc. COR slid 2.56% to $254.00 Wednesday, on what proved to be an all-around mixed trading session for the ...
2d
Barchart on MSNIs Cencora Stock Outperforming the Nasdaq?With a market cap of $50.5 billion, Conshohocken, Pennsylvania-based Cencora, Inc. (COR) is a global healthcare solutions ...
Cencora (NYSE:COR) has made headlines with its announcement on March 10, 2025, detailing plans for strategic acquisitions and investments in technology infrastructure, aiming to drive future growth.
4h
Zacks Investment Research on MSNCVS Health (CVS) Down 0.9% Since Last Earnings Report: Can It Rebound?It has been about a month since the last earnings report for CVS Health (CVS). Shares have lost about 0.9% in that time frame, outperforming the S&P 500. Will the recent negative trend continue ...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. Learn more on COR stock here.
AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...
In this article, we are going to take a look at where Cencora, Inc. (NYSE:COR) stands against other stocks with at least $30 million in insider sales recently. Last week, stocks declined in part ...
Shares of Cencora Inc. COR advanced 1.82% to $253.54 Friday, on what proved to be an all-around favorable trading session for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results